COMBINATION THERAPY OF INHIBITORS FOR IGF1 R AND PI3K

摘要

The present invention relates to a pharmaceutical combination comprising an alpha- isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine- 1,2-dicarboxylic acid 2-amide l-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin- 4-yl]-thiazol-2-yl}-amide), or pharmaceutically acceptable salt thereof, and an IGF1R inhibitor (e.g., the IGF1R inhibitor ANTIBODY A, or a variant or derivative thereof), a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of therapeutically effective amounts of such inhibitors to a subject in need thereof, and uses of such combination for the treatment of cancer.